Does age affect who can use semaglutide for weight loss?

Is there a minimum age for semaglutide in the UK?

Yes. Wegovy (semaglutide injection) and the newer oral Wegovy tablet are both licensed for adults, meaning people aged 18 and over. That is not a nume policy; it reflects the MHRA-approved licence for both products, and it is the floor below which a UK prescriber cannot go. If you are a parent researching this for a teenager, the honest answer is that these medicines are not approved for that age group in the UK, and a GP or paediatrician is the right starting point for adolescent weight concerns.

The age-18 minimum applies regardless of BMI. A 17-year-old with a BMI of 40 and type 2 diabetes is still outside the licensed indication for Wegovy as a weight-management medicine in the UK. Prescribers follow the licence; the licence exists because the clinical trials that support it enrolled adults. You can read more about how semaglutide works for context on what those trials established, including details on the semaglutide 1 mg dose that forms part of the escalation schedule.

One thing worth knowing: the NICE recommendation for semaglutide (TA875) places additional conditions on top of the licence (BMI thresholds, comorbidities, specialist service involvement) but it does not change the minimum age. The licence minimum of 18 stands regardless of commissioning criteria, and the semaglutide 2 mg dose guidance similarly applies only within that licensed adult population.

Is there a maximum age at which semaglutide stops being appropriate?

No fixed upper limit exists in the UK licence. The NHS patient information for semaglutide does not set a ceiling; older adults in good general health can be considered in the same way as younger ones, provided the prescriber is satisfied that the benefits outweigh any risks for that individual.

That said, age does bring clinical complexity. Kidney function tends to decline gradually over decades, and because semaglutide slows gastric emptying and can cause nausea and reduced appetite, dehydration is a real concern if GI side effects hit hard. For someone already on several medicines (common in older adults managing blood pressure, cholesterol, or diabetes) the prescriber needs to think carefully about interactions and about whether the appetite reduction that comes with treatment might tip someone into undernutrition rather than healthy weight loss.

None of this disqualifies older adults automatically. It means the consultation carries more weight, not less. For a fuller picture of age-related considerations alongside Wegovy specifically, the Wegovy and age page sets out what the evidence says about older patient outcomes.

What does the clinical evidence say about semaglutide in different age groups?

The STEP 1 trial (the pivotal phase-3 study published in the New England Journal of Medicine) enrolled adults across a wide age range and found an average body-weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose, alongside lifestyle changes. The trial enrolled over 1,900 adults without diabetes; the age range was broad, though the median participant was in their mid-forties.

Subgroup analyses from the STEP programme suggest that efficacy is broadly preserved across age groups, though older adults may lose weight somewhat more slowly and the absolute magnitude of loss can vary. What the trials consistently show is that GI side effects (nausea, loose stools, occasional vomiting) are the most common reason people reduce their dose or pause treatment, and older patients with less physiological reserve need to stay well hydrated. Our prescribers flag this during every consultation, not just as a warning but as practical advice: small meals, sufficient fluid, and not skipping the dose-escalation steps.

If you are comparing semaglutide to tirzepatide and wondering which suits your age group better, a consultation is the only place to get a personalised answer. The broader comparison between the two medicines is covered on the Wegovy treatment page.

What changes about the consultation if you are older?

The process is identical in structure (a free online consultation reviewed the same day by a GPhC-registered prescriber, never an automated system) but the clinical territory is wider. Prescribers at a service like nume look at current medications more carefully, because semaglutide's effect on gastric emptying can alter how quickly some oral medicines are absorbed. That matters particularly for anyone taking levothyroxine, some blood-pressure tablets, or certain anticoagulants first thing in the morning.

For anyone considering the oral Wegovy tablet, the morning routine is specific: one tablet on an empty stomach before anything else (food, coffee, or other medicines) with a small amount of plain water, then a wait of at least 30 minutes. That rhythm is straightforward enough for most people, but it is worth thinking through honestly before starting. It is one of the questions our clinical team covers. For context on how Wegovy is priced privately, that page explains what a transparent consultation-to-delivery service includes. And if you want to read more about the prescribers behind num's clinical review, our clinical team page sets out who is involved.

If you have questions that are not covered here, the FAQs are a good next stop, or you can get in touch directly. When you are ready, the free consultation is where the clinical conversation starts.